As filed · SMS Pharmaceuticals Limited has informed the Exchange about General Updates
Limited Review Report for for the quarter and half-year ended 30th September, 2026. (Standalone & Consolidated) Financial Results along with the limited review report.
Reported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
Prior statements by this company that CapitSignal has recorded changing.
Our revenue reached ₹783 crore, marking a 10% increase over the previous year, supported by steady demand across our therapeutic portfolio.
Anti-inflammatory products, led by ibuprofen, grew 22% year-on-year to ₹148 crore.
Anti-inflammatory products, led by ibuprofen, grew 22% year-on-year to ₹148 crore.
ARVs delivered 15% growth, contributing ₹163 crore, reaffirming our established presence in this segment.
ARVs delivered 15% growth, contributing ₹163 crore, reaffirming our established presence in this segment.
The anti-epileptic segment grew with notable momentum, more than doubling to ₹29 crore on the back of expanded access in regulated markets.
